Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)








2-N-DIBUTYLAMIN						Print
																Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 102-81-8; **Chemical Formula:** (C4H9)2NCH2CH2OH
OSHA formerly had no limit for 2-N-dibutylaminoethanol (DBAE). The ACGIH has a TLV-TWA of 2 ppm, with a skin notation, for this colorless, combustible liquid, which has a faint, amine-like odor. The proposed PEL was 2 ppm as an 8-hour TWA. NIOSH (Ex. 8-47) concurred with this limit, and this is the limit established by the final rule. The proposed skin notation is not retained in the final rule.
In rats, 2-N-dibutylaminoethanol has a single-dose oral LD(50) of 1.7 g/kg and a corresponding intraperitoneal LD(50) of 0.14 g/kg; these values are approximately analogous to the oral and intraperitoneal LD(50)s for diethanolamine (Hartung and Cornish 1968/Ex. 1-328). The LD(50) for skin absorption in rabbits is 1.68 g/kg (Smyth, Carpenter, Weil, and Pozzani 1954/Ex. 1-440). In male rats, the lowest five-week drinking water dose tolerated without weight loss was 0.13 g/kg/day. Rats that ingested a dose of 0.43 g/kg/day showed elevated kidney-to-body-weight ratios but no histologic changes at autopsy (Cornish, Dambrauskas, and Beatty 1969/Ex. 1-411). In inhalation studies of rats, 6-hour exposures at 70 ppm for five days killed one rat; the surviving rats showed a 57-percent average body weight loss, as well as a doubling of kidney-to-body-weight ratios, a tenfold increase in serum bilirubin, a slight increase in clotting time,and an elevated hematocrit. Inhalation of 33 ppm for one week caused a 3-percent body weight loss and a slight increase in clotting time, but significant changes in the other variables observed. Twenty-seven weeks of exposure to 22 ppm resulted in no differences between exposed rats and controls in the variables measured (Cornish, Dambrauskas, and Beatty 1969/Ex. 1-411). 2-N-dibutylaminoethanol is a more potent inhibitor of acetylcholinesterase in vitro than is diethylamine (DEA) (Hartung and Cornish 1968/Ex. 1-328). NIOSH was the only commenter to the rulemaking record for DBAE.
In the final rule, OSHA is establishing an 8-hour TWA PEL of 2 ppm for 2-N-dibutylaminoethanol. The Agency concludes that this limit will protect workers from the significant risk of metabolic effects associated with inhalation exposure at the levels permitted in the absence of any OSHA limit. OSHA has determined that this substance does not present a significant risk of systemic toxicity via percutaneous absorption (2-N-dibutylaminoethanol’s dermal LD(50) in rabbits is 1.68 g/kg) and therefore, that no skin notation is required. Accordingly, the skin notation proposed for DBAE is not retained in the final rule.
							
					
							Last Reviewed:  September 28, 2011						Source: 	National Institute for Occupational Safety and Health
					Facebook
        Twitter
        LinkedIn
        Syndicate NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue